A new study published in the Journal of the European Academy of Dermatology and Venereology revealed that subcutaneous methotrexate (MTX) improves treatment efficacy for psoriasis compared to oral MTX but also carries a higher risk of adverse effects. Oral MTX showed higher discontinuation due to ineffectiveness, whereas subcutaneous MTX had more discontinuations related to side effects.

From July 2012 to January 2023, this study included 406 patients diagnosed with plaque, erythrodermic, or guttate psoriasis. All participants were new to methotrexate, biologic therapies, and apremilast, and began treatment with MTX monotherapy. Among them, 58.1% received oral methotrexate (MTX-PO), while 41.9% were administered the drug subcutaneously (MTX-SC).

At the start of treatment, the median Ps

See Full Page